Five patients received CAR-T therapy injections in october 2024, according to researchers from the Chinese university of Hong Kong. These patients' health is getting much better.
Patients report feeling better than they did previously. Also, the ache has subsided.
Hong Kong has made a major claim on the cancer-curing CAR-T injection. The five patients who received CAR-T injections in november 2024 are all progressively getting better, according to hong kong scientists. The responses of those individuals have also been shared by scientists. Following this result, there may be a global surge in demand for Hong Kong's CAR-T injection.
In october 2024, five patients at the Chinese university of hong kong received this injection, according to the South china Morning Post. One patient, who had this injection, is 73 years old; the other is 71; the third is 67; the fourth is 15; and the fifth is 5 years old.
According to scientists, many patients saw significant improvement by February. These patients had improved from previously. These patients' words, in which they describe their experiences, have also been documented by scientists.
Lee Chung, a cancer patient, said this procedure just took a few minutes. Then, slowly, I began to feel better. The illness is quickly becoming better, and there is no longer any agony. Scientists from hong kong assert that following this advancement, CAR-T injections may prove beneficial for cancer patients.
CAR-T injection costs
The article claims that this vaccine is still well out of reach for the average person. The vaccine costs just Rs 3 crore when side effects and other costs are excluded. Hong Kong is the basis for this price. This implies that the cost of this injection can go up even more in other nations.
The patient must remain in the intensive care unit for seven days following the injection. Each side effect is handled independently. Furthermore, this injection has only been shown to be successful in treating lung or liver cancer thus far.
The state of this treatment in india
IIT bombay initiated this therapy in india in 2023. Nexcar-19 is used to administer CAR-T treatment to patients in India. This therapy is made in India. Through Made in india, the central government is attempting to offer vaccines to patients at a reasonable cost.
The treatment india is developing may help treat blood cancer, according to Nature magazine.
Patients report feeling better than they did previously. Also, the ache has subsided.
Hong Kong has made a major claim on the cancer-curing CAR-T injection. The five patients who received CAR-T injections in november 2024 are all progressively getting better, according to hong kong scientists. The responses of those individuals have also been shared by scientists. Following this result, there may be a global surge in demand for Hong Kong's CAR-T injection.
In october 2024, five patients at the Chinese university of hong kong received this injection, according to the South china Morning Post. One patient, who had this injection, is 73 years old; the other is 71; the third is 67; the fourth is 15; and the fifth is 5 years old.
According to scientists, many patients saw significant improvement by February. These patients had improved from previously. These patients' words, in which they describe their experiences, have also been documented by scientists.
Lee Chung, a cancer patient, said this procedure just took a few minutes. Then, slowly, I began to feel better. The illness is quickly becoming better, and there is no longer any agony. Scientists from hong kong assert that following this advancement, CAR-T injections may prove beneficial for cancer patients.
CAR-T injection costs
The article claims that this vaccine is still well out of reach for the average person. The vaccine costs just Rs 3 crore when side effects and other costs are excluded. Hong Kong is the basis for this price. This implies that the cost of this injection can go up even more in other nations.
The patient must remain in the intensive care unit for seven days following the injection. Each side effect is handled independently. Furthermore, this injection has only been shown to be successful in treating lung or liver cancer thus far.
The state of this treatment in india
IIT bombay initiated this therapy in india in 2023. Nexcar-19 is used to administer CAR-T treatment to patients in India. This therapy is made in India. Through Made in india, the central government is attempting to offer vaccines to patients at a reasonable cost.
The treatment india is developing may help treat blood cancer, according to Nature magazine.
click and follow Indiaherald WhatsApp channel